Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma
We describe the design of a set of inhibitors to investigate the relationship between cyclin G associated kinase (GAK) and epidermal growth factor receptor (EGFR) in chordoma bone cancers. These compounds were characterized both in vitro and using in cell target engagement assays. The most potent chordoma inhibitors were further characterized in a kinome-wide screen demonstrating narrow spectrum profiles. While we observed a direct correlation between EGFR and antiproliferative effects on chordoma, GAK inhibition appeared to have only a limited effect.
Authors
- Christopher R. M. Asquith (ORCID: https://orcid.org/0000-0001-5871-3458)
- Kaleb M. Naegeli (ORCID: https://orcid.org/0000-0002-7551-4108)
- David C. Morris (ORCID: https://orcid.org/0000-0002-2910-7544)
- Tammy M. Havener (ORCID: https://orcid.org/0000-0002-4613-0498)
- William J. Zuercher (ORCID: https://orcid.org/0000-0002-9836-0068)
- Gary L. Johnson (ORCID: https://orcid.org/0000-0003-2867-0551)
- Tuomo Laitinen (ORCID: https://orcid.org/0000-0003-1539-2142)
- Michael P. East (ORCID: https://orcid.org/0000-0002-1994-6117)
- Carrow I. Wells (ORCID: https://orcid.org/0000-0003-4799-6792)
- David H. Drewry (ORCID: https://orcid.org/0000-0001-5973-5798)
Institutions
- University of North Carolina at Chapel Hill (US)
Publication Details
- Journal
- UNC Libraries
- Published
- 2025-10-10
- DOI
- https://doi.org/10.17615/vqv9-re22
- Primary Topic
- Neurofibromatosis and Schwannoma Cases
- Type
- article
- Field-Weighted Citation Impact
- 0.00